The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: Results from the Australian HIV observational database

Journal of Clinical Virology

Volumn 26, Issue 2, 2003, Pages 209-222

  Petoumenos, Kathy ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiretroviral treatment; Disease progression; HIV; Observational cohorts

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; AUSTRALIA; CAUSE OF DEATH; COHORT ANALYSIS; DATA BASE; DISEASE COURSE; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; OBSERVATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; HIV; HIV INFECTIONS; HUMANS; POPULATION SURVEILLANCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037319301     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(02)00119-1     Document Type: Article

References (45)

1. AHOD (The Australian HIV Observational Database). Time trends in antiretroviral treatment use in Australia, 1997-2000, Venereology 2000;14:162-168.
2. AHOD (The Australian HIV Observational Database). Rates of combination antiretroviral treatment change in Australia, 1997-2000, HIV Med,2002:3:28-36
3. Becker S.L., Raffanti S.R., Hansen N.I., Fusco J.S., Fusco G.P., Slatko G.H., Igboko E.F., Graham N.M. Zidovudine and Stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. JAIDS. 26:2001;72-81.
4. Benson C.A. Structured treatment interruption in HIV infection. AIDS Reader. 11:2001;99-102.
5. Cameron D.W., Japour A.J., Xu Y., Hsu A., Mellors J., Farthing C., Cohen C., Poretz D., Markowitz M., Follansbee S., Angel J.B., McMahon D., Ho D., Devanarayan V., Rode R., Salgo M., Kempf D.J., Granneman R., Leonard J.M., Sun E. Ritonavir and Saquinavir combination therapy for the treatment of HIV infection. AIDS. 13:1998;213-224.
6. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., Cooper D.A. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-F58.
7. Carr A., Miller J., Law M., Cooper D.A. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 14:2000;F25-F32.
8. Correll P.K., Law M.G., McDonald A.M., Cooper D.A., Kaldor J.M. HIV disease progression in Australia in the time of combination antiretroviral therapies. Med. J. Aust. 169:1998;469-472.
9. Cozzi Lepri A., Miller V., Phillips A.N., Rabenau H., Sabin C., Staszewski S. The virological response to highly active antiretroviral therapy over the fist 24 weeks of therapy according to pre-therapy viral load and the weeks 4-8 viral load. AIDS. 15:2001;47-54.
10. Cozzi Lepri A., Phillips A.N., d'Arminio Monforte A., Castelli F., Antinori A., de Luca A., Pezzotti P., Alberici F., Cargnel A., Grima P., Piscopo R., Prestileo T., Scalise G., Vigevani M., Moroni M. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS. 15:2001;983-990.
11. CTARC (HIV/AIDS Clinical Trials and Research Committee of the Australian National Council on AIDS, Hepatitis C and Related Diseases). Draft 2001 Australian Antiretroviral Guidelines (edited by Jenny Hoy) October 2001, Available at: http://www.ashm.org.au/uploadFile/GUIDELINES2.pdf .
12. Egger M., Hirschel B., Francioli P., Sudre P., Wirz M., Flepp M., Rickenbach M., Malinverni R., Vernazza P., Battegay M. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br. Med. J. 315:1997;1194-1199.
13. Erb P., Battegay M., Zimmerli W., Rickenbach M., Egger M. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Arch. Int. Med. 160:2000;1134-1140.
14. Fatkenheuer G., Theisen A., Rockstroh J., Grabow T., Wicke C., Becker K., Wieland U., Pfister H., Reiser M., Hegener P., Franzen C., Schwenk A., Salzberger B. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 11:1997;F113-F116.
15. Grabar S., Pradier C., Le Corfec E., Lancar R., Allavena C., Bentata M., Berlureau P., Dupont C., Fabbro-Peray P., Poizot-Martin I., Costagliola D. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 14:2000;141-149.
16. Graham N.M. Studies of Antiretroviral therapy in the Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17:1998;S9-S12.
17. Junghans C., Low N., Chan P., Witschi A., Vernazza P., Egger M. Uniform risk of clinical progression despite differences in utilisation of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS. 13:1999;2547-2554.
18. Kaufmann G.R., Duncombe C., Cunningham P., Beveridge A., Carr A., Sayer D., French M., Cooper D.A. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort. AIDS. 12:1998;1625-1630.
19. Law M.G., Anderson J., Cui J., Duncombe C., Mallal S., Roth N., Fagan D., Smith D., Bloch M., Grulich A. Trends in antiretroviral treatment for people with HIV in Australia: an observational database pilot study. Venereology. 12:1999;97-103.
20. Law M.G., Li Y., McDonald A.M., Cooper D.A., Kaldor J.M. Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. AIDS. 14:2000;197-201.
21. Ledergerber B., Egger M., Erard V., Weber R., Hirschel B., Furrer H., Battegay M., Vernazza P., Bernasconi E., Opravil M., Kaufmann D., Sudre P., Francioli P., Telenti A. AIDS related opportunistic illness occurring after initiation of potent antiretroviral therapy. J. Am. Med. Assoc. 282:1999;2220-2226.
22. Lundgren J.D., Phillips A.N., Vella S., Katlama C., Ledergerber B., Johnson A.M., Reiss P., Gatell J., Clumeck N., Dietrich M., Benfield T.L., Nielsen J.O., Pedersen C. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. JAIDS. 16:1997;153-160.
23. Mallal S.A., John M., Moore C.B., James I.R., McKinnon E.J. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 14:2000;1309-1316.
24. Martinez E., Mocroft A., Garcia-Viejo M.A., Perez-Cuevas J.B., Blanco J.L., Mallolas J., Bianchi L., Conget I., Blanch J., Phillips A., Gatell J.M. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 357:2000;532-598.
25. Merry C., Barry M.G., Mulcahy F., Halifax K.L., Back D.J. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 11:1997;F29-F33.
26. Miller V., Sabin C.A., Phillips A.N., Rottmann C., Rabenau H., Weidmann E., Rickerts V., Findhammer S., Helm E.B., Staszewski S. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS. 14:2000;2129-2136.
27. Miller V., Sabin C., Hertogs K., Bloor S., Martinez-Picado J., D'Aquila R., Larder B., Lutz T., Gute P., Weidmann E., Rabenau H., Phillips A., Staszewski S. Virological and immunological effects of treatment interruption in HIV-1 infected patients with treatment failure. AIDS. 14:2000;2857-2867.
28. Mocroft A., Vella S., Benfield T.L., Chiesi A., Miller V., Gargalianos P., d'Arminio M.A., Yust I., Bruun J.N., Phillips A.N., Lundgren J.D. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 352:1998;1725-1730.
29. Mocroft A., Gill M.J., Davidson W., Phillips A.N. Predictors of viral response and subsequent virological treatment failure in patients with HIV starting a PI. AIDS. 12:1998;2161-2167.
30. Morlat P., Marimoutou C., Dequae-Merchadou L., Pellegrin I., Mercie P., Neau D., Beylot J., Dabis F. Dual nucleoside regimens in non-advanced HIV infection: prospective follow-up of 130 patiens, Aquitaine cohort, 1996-1998. JAIDS. 23:2000;255-260.
31. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Reader. 11:2001;87-98.
32. National Centre in HIV Epidemiology and Clinical Research. Australian HIV Observational Database. Biannual Report, vol. 2, No. 2. December 2001a. Sydney: NCHECR, University of NSW, 2001.
33. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, Hepatitis C and sexually transmissible infections in Australia: annual surveillance report 2001b. Sydney: NCHECR, University of NSW, 2001.
34. Neumann A.U., Tubiana R., Calvez V., Robert C., Li T.S., Agut H., Autran B., Katlama C. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS. 13:1999;677-683.
35. Paredes R., Mocroft A., Kirk O., Lazzarin A., Barton S.E., van Lunzen J., Katzenstein T.L., Antunes F., Lundgren J.D., Clotet B. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch. Int. Med. 160:2000;1123-1132.
36. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M, For the EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomised trials. AIDS 1999;13:2075-82.
37. Piketty C., Castiel P., Belec L., Batisse D., Si Mohamed A., Gilquin J., Gonzalez-Canali G., Jayle D., Karmochkine M., Weiss L., Aboulker J.P., Kazatchkine M.D. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 12:1998;745-750.
38. Rhone S.A., Hogg R.S., Yip B., Sherlock C., Conway B., Schechter M.T., O'Shaughnessy M.V., Montaner J.S. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS. 12:1998;619-624.
39. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B.M., Eldridge R.L., Robbins G.K., D'Aquila R.T., Goulder P.J.R., Walker B.D. Immune control of HIV-1 after early treatment of acute infection. Nature. 407:2000;523-526.
40. Ruiz L., Martinez-Picado J., Romeu J., Paredes R., Zayat M.K., Marfil S., Negredo E., Sirera G., Tural C., Clotet B. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS. 14:2000;397-403.
41. Staszewski S., Miller V., Sabin C., Carlebach A., Berger A.M., Weidmann E., Helm E.B., Hill A., Phillips A. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 13:1999;367-373.
42. Tarwater P.M., Margolick J.B., Jin J., Phair J.P., Detels R., Rinaldo C., Giorgi J., Munoz A. Increase and plateau of CD4 T-cell counts in the 3 1/2 years after initiation of potent antiretroviral therapy. JAIDS. 27:2001;168-175.
43. Viard J.P., Mocroft A., Chiesi A., Kirk O., Roge B., Panos G., Vetter N., Bruun J.N., Johnson M., Lundgren J.D. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J. Infect. Dis. 183:2001;1290-1294.
44. Weidle P.J., Holmberg S.D., DeCock K.M. Changes in HIV and AIDS epidemiology from new generation antiretroviral therapy. AIDS. 13:1999;S61-S68.
45. Yamashita T.E., Phair J.P., Munoz A., Margolick J.B., Detels R., O'Brien S.J., Mellors J.W., Wolinsky S.M., Jacobson L.P. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS. 15:2001;735-746.